In 2002, randomised controlled trials demonstrated that therapeutic hypothermia is an effective measure to improve neurological outcome in patients after cardiac arrest. 1 2 Based on the patient groups included in these trials the International Liaison Committee on Resuscitation recommended this treatment in 2003 for all comatose survivors after out-of-hospital cardiac arrest due to ventricular fibrillation (VF). In addition, the International Liaison Committee on Resuscitation stated that patients with other rhythms might also benefit from therapeutic hypothermia. 3 Consequently, many published hypothermia protocols used in daily clinical practice include patients after cardiac arrest independently of the initial rhythm and report no relevant side effects. 4 5 It is well known that patients resuscitated from non-VF share a poor prognosis. 6 At present there is little knowledge on whether therapeutic hypothermia improves outcomes in patients resuscitated from non-shockable (asystole, pulseless electrical activity; PEA) cardiac arrest as it does in patients resuscitated from shockable rhythm (VF). 7 Therefore we conducted a single centre prospective observational database including patients after cardiac arrest admitted to our intensive care unit (ICU) between 2002 and 2010. This is a subanalysis of patients with non-shockable initial rhythm. Due to the implementation of mild therapeutic hypothermia in recent years we compared controls (nonhypothermia group) included before the era of hypothermia with cardiac arrest patients undergoing cooling treatment (hypothermia group).
METHODS
The study protocol was approved by the local ethics committee on human research. Neurological outcome was defined at the time of discharge from the ICU according to the Pittsburgh cerebral performance category (CPC) while the defining physician on duty was blinded to the study. 8 CPC 1 and 2 were classified as a favourable neurological outcome, whereas CPC 3, 4 and 5 were regarded as an unfavourable outcome. A follow-up concerning mortality was completed for all patients after 90 days.
SPSS software (version 17.0) was used for statistical analysis. Descriptive parameters are given as median and IQR (25the75th percentiles). Univariate analysis of differences between hypothermia patients and the control group was performed by using the ManneWhitney U test for non-parametric unpaired data and Fisher's exact test for dichotomous variables. Survival data were analysed by the KaplaneMeier analysis and comparison between groups was performed by the log rank test, Cox regression was used to adjust for confounders. Figure 1 shows patient recruitment. The results of univariate analysis are given in table 1. Hypothermia treatment was associated with improved neurological outcome without reaching a level of significance in patients resuscitated from non-VF cardiac arrest (CPC 1e2: hypothermia 27.59% vs control 18.20%, p¼0.175). Differences between unfavourable outcome and death were only minor (CPC 3e5: hypothermia 72.41%, control 81.80%; CPC 5: hypothermia 58.62%, control 63.64%, p¼1.00) (table 2) .
RESULTS
Patients in the hypothermia group tended to have a shorter duration of ventilator treatment (hypothermia 149 h, 80e407 IQR; non-hypothermia 193 h, 93e340 IQR, p¼0.16) and a shorter stay in the ICU (hypothermia 8 days, 4e27 IQR; non-hypothermia 11.5 days, 6e22 IQR, p¼0.05) without reaching a level of significance, whereas time to return of spontaneous circulation (ROSC; hypothermia 16 min, 12e25 IQR; non-hypothermia 20 min, 12e30 IQR, p¼0.02) and epinephrine dosage (hypothermia 2 mg, 1e4 IQR; non-hypothermia 3 mg, 2e5 IQR, p<0.01) was significantly lower in patients undergoing hypothermia treatment.
KaplaneMeier analysis after 90 days revealed no significant benefit for the hypothermia group (log rank test p¼0.82), and Cox regression showed no statistically significant improvement for survival ( figure 2 and table 3 ).
DISCUSSION
Only a minority of published data are concerned with the role of mild therapeutic hypothermia in patients with initially nonshockable rhythm. 9 Published guidelines from the Clinical Practice Committee of the Scandinavian Society of Anaesthesiology for Hypothermia recommend hypothermia also after Figure 1 Chart of study design. HT, hypothermia treatment; TH, therapeutic hypothermia; VF, ventricular fibrillation.
non-VF rhythms. 7 In a recent study the initial rhythm (VF vs non-VF) was not a predictor for survival in logistic regression analysis in survivors after out-of-hospital cardiac arrest. 10 A case series published by Foedisch et al 11 including 49 survivors after cardiac arrest (31/49 presenting with VF/ventricular tachycardia, 17/49 presenting with asystole) reported favourable neurological outcomes in seven patients with asystole as the initial rhythm (41%). The authors concluded that therapeutic hypothermia might be beneficial in patients after non-VF cardiac arrest. 11 However, data published by Hay et al 12 reported a favourable neurological outcome in only 7% of the non-VF patients in a study of 139 survivors after out-of-hospital cardiac arrest. Another current study revealed a 16.7% survival rate, 8.3% with good outcome, in 74 patients treated with hypothermia after non-shockable cardiac arrest. 10 Based on our results, hypothermia failed to improve significantly the number of patients with favourable outcomes at ICU discharge (survival rate 41.3%; good outcome 27.6%). In KaplaneMeier analysis and Cox regression no statistically significant benefit concerning mortality was observed either.
Some limitations of our study have to be emphasised. First of all the results presented were generated in an observational fashion using historical controls. Although ICU treatment did not change substantially, in general the possibility that in some cases treatment differed over the years cannot be fully excluded. As an example, time on ventilator was shorter in our hypothermia group. Obviously this result may not only be attributed to hypothermia itself but also to the increased use of lung protective strategies. Furthermore, patients with initially nonshockable cardiac arrest represent a very heterogeneous patient group. 10 In addition, the time to ROSC and epinephrine dosage was significantly shorter in the hypothermia group, whereas the Acute Physiology and Chronic Health Evaluation (APACHE) score was higher compared with the control group. In order to compensate for this heterogeneity, studies with larger patient groups are required. When using historical controls there may be effects due to the fact that the introduction of therapeutic hypothermia itself has focused the physicians in charge to more sophisticated post-resuscitation care in general. Another limitation may be that we cannot provide follow-up data regarding the CPC score after 90 days. Although recent studies show that CPC does not change significantly in the first months after discharge, it might possible that even minor changes may have an important impact on patients' quality of life. 9 13 Nevertheless, our data suggest no statistically significant beneficial effects of therapeutic hypothermia in this patient group. Of course, data from different centres are hardly comparable as a result of different standard operating procedures or local conditions, therefore in the future only a multicentre randomised controlled trial can identify the possible benefit of hypothermia for non-shockable cardiac arrest patients and can provide adequate control for confounders. Because of the trend towards a better neurological outcome (non-significant) in the hypothermia group (CPC 1e2: hypothermia 27.59% vs control 18.20%, p¼0.175) the ethical component of a randomised study design needs to be discussed. On the basis of our results a sample size of 670 patients (1b 0.80; a 0.05) is needed to test the hypothesis appropriately concerning neurological outcomes between hypothermia and non-hypothermia-treated patients.
In summary, there was no statistically significant benefit but only a trend towards a more favourable neurological outcome for the hypothermia group. There was no benefit in short-term 90-day mortality.
Following our results hypothermia treatment needs to be evaluated in a large multicentre trial for cardiac arrest survivors with initially non-shockable rhythms to clarify whether cooling may also be beneficial for other rhythms than VF.
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Images in emergency medicine
'Scurvy': presentation and skin manifestations of a not so uncommon condition
An 84-year-old man attended our emergency department with a 5-month history of poor oral intake since the death of his wife. He complained of lethargy, dyspnoea, epistaxis and myalgic pains. He was severely thin with purpuric skin lesions over his knuckles, elbows and shins (figures 1 and 2).
1
Scurvy was suggested and confirmed by dermatology. The patient was started on ascorbic acid (400 mg/24 h) and initially improved, but died later of a nosocomial infection.
Scurvy is a state of vitamin C (ascorbic acid) deficiency. Ascorbic acid is used in the synthesis of collagen, neurotransmitters and helps in dietary iron absorption. Deficiency results in poor wound healing, defective capillary walls and anaemia.
The UK incidence of clinical scurvy is unknown, but the prevalence of vitamin C deficiency is estimated at 25% in men and 16% in women and is associated with low income, poor diet and smoking.
1 Symptoms/signs include lethargy, purpura, epistaxis, myalgia, dyspnoea, spongy gums and tooth loss. Complications include haemorrhage, neuropathies, immunocompromise and hepatic and renal failure.
Scurvy is believed to be historical or a diagnosis of developing countries. However, it is more common than perceived. Patients can easily be treated with dietary input and ascorbic acid supplementation. Symptoms often resolve in 1e2 weeks. 
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